GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:00226047 | Liver | NAFLD | regulation of cell morphogenesis | 62/1882 | 309/18723 | 8.35e-08 | 7.09e-06 | 62 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00071606 | Liver | NAFLD | cell-matrix adhesion | 49/1882 | 233/18723 | 4.36e-07 | 2.74e-05 | 49 |
GO:00108107 | Liver | NAFLD | regulation of cell-substrate adhesion | 47/1882 | 221/18723 | 5.30e-07 | 3.16e-05 | 47 |
GO:0031639 | Liver | NAFLD | plasminogen activation | 12/1882 | 24/18723 | 8.76e-07 | 4.60e-05 | 12 |
GO:1903035 | Liver | NAFLD | negative regulation of response to wounding | 26/1882 | 94/18723 | 1.18e-06 | 5.66e-05 | 26 |
GO:00315896 | Liver | NAFLD | cell-substrate adhesion | 65/1882 | 363/18723 | 2.84e-06 | 1.18e-04 | 65 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGB | SNV | Missense_Mutation | | c.490N>T | p.Asp164Tyr | p.D164Y | P02675 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-75-5126-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | | c.266N>A | p.Ala89Asp | p.A89D | P02675 | protein_coding | tolerated(0.26) | benign(0.1) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | | c.823N>A | p.Glu275Lys | p.E275K | P02675 | protein_coding | tolerated(0.53) | benign(0.104) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FGB | SNV | Missense_Mutation | novel | c.184G>C | p.Ala62Pro | p.A62P | P02675 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.692) | TCGA-21-1083-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | | c.387N>C | p.Glu129Asp | p.E129D | P02675 | protein_coding | tolerated(0.47) | benign(0) | TCGA-22-5485-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
FGB | SNV | Missense_Mutation | novel | c.269N>T | p.Pro90Leu | p.P90L | P02675 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-33-AASD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FGB | SNV | Missense_Mutation | novel | c.1379N>T | p.Gly460Val | p.G460V | P02675 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-34-8455-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
FGB | SNV | Missense_Mutation | novel | c.881N>T | p.Arg294Met | p.R294M | P02675 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-56-7730-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
FGB | SNV | Missense_Mutation | novel | c.1184N>A | p.Arg395Lys | p.R395K | P02675 | protein_coding | tolerated(0.69) | benign(0.029) | TCGA-85-7844-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | | c.1292N>A | p.Gly431Glu | p.G431E | P02675 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-85-8582-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | inhibitor | CHEMBL1201505 | FIBRINOLYSIN, HUMAN | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | RECOMBINANT FACTOR IX FC FUSION PROTEIN | | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | HAEMATOXYLIN | HAEMATOXYLIN | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | eptifibatide | EPTIFIBATIDE | 20938371 |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | ALFIMEPRASE | ALFIMEPRASE | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | abciximab | ABCIXIMAB | 20938371 |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | tirofiban | TIROFIBAN | 20938371 |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | | METHYLTHIONINIUM CHLORIDE | METHYLTHIONINIUM CHLORIDE | |